Clinical outcomes of pediatric macular edema associated with non-infectious uveitis

被引:3
|
作者
Nguyen, Anh Hong [1 ]
Mekonnen, Bethlehem [1 ]
Kim, Eric [2 ]
Acharya, Nisha R. [1 ,2 ,3 ]
机构
[1] Univ Calif San Francisco, Dept Ophthalmol, 490 Illinois St,2nd Floor, San Francisco, CA 94158 USA
[2] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA USA
[3] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
基金
美国国家卫生研究院;
关键词
Pediatric uveitis; Macular edema; OCT;
D O I
10.1186/s12348-021-00236-4
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background Macular edema (ME) is the most frequent cause of irreversible visual impairment in patients with uveitis. To date, little data exists about the clinical course of ME in pediatric patients. A retrospective, observational study was performed to examine the visual and macular thickness outcomes of ME associated with chronic, noninfectious uveitis in pediatric patients. Methods Pediatric patients with noninfectious uveitis complicated by ME seen in the University of California San Francisco Health System from 2012 to 2018 were identified using ICD-9 and ICD-10 codes. Data were collected from medical records including demographics, diagnoses, ocular history, OCT imaging findings, complications, and treatments at first encounter and at 3, 6, 9, and 12-month follow-up visits. Cox proportional hazards regression was used to investigate the association between different classes of treatment (steroid drops, steroid injections, oral steroids and other immunosuppressive therapies) and resolution of macular edema. Results The cohort comprised of 21 children (26 eyes) with a mean age of 10.5 years (SD 3.3). Undifferentiated uveitis was the most common diagnosis, affecting 19 eyes (73.1%). The majority of observed macular edema was unilateral (16 patients, 76.2%) and 5 patients had bilateral macular edema. The mean duration of follow-up at UCSF was 35.3 months (SD 25.7). By 12 months, 18 eyes (69.2%) had achieved resolution of ME. The median time to resolution was 3 months (IQR 3-6 months). Median best-corrected visual acuity (BCVA) at baseline was 0.54 logMAR (Snellen 20/69, IQR 20/40 to 20/200). Median BCVA at 12 months was 0.1 logMAR (Snellen 20/25, IQR 20/20 to 20/50) Corticosteroid injections were associated with a 4.0-fold higher rate of macular edema resolution (95% CI 1.3-12.2, P = 0.01). Conclusions Although only 15% of the pediatric patients with uveitis in the study cohort had ME, it is clinically important to conduct OCTs to detect ME in this population. Treatment resulted in 69% of eyes achieving resolution of ME by 12 months, accompanied with improvement in visual acuity. Corticosteroid injections were significantly associated with resolution of macular edema.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Brain MRI White Matter Abnormalities in Pediatric Non-Infectious Uveitis
    Maccora, Ilaria
    Hendrikse, Jytte
    Ayuso, Viera Kalinina
    Gatti, Laura
    Brandsma, Rick
    Corbelli, Laura
    Jansen, Marc H.
    de Libero, Cinzia
    Nievelstein, Rutger A. J.
    Caputo, Roberto
    Simonini, Gabriele
    de Boer, Joke H.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2024,
  • [42] Intravitreal dexamethasone implant (ozurdex®) in macular oedema secondary to non-infectious uveitis
    James, B.
    Vaideanu-Collins, D.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (07) : 1625 - 1626
  • [43] Follow-up Findings of Non-infectious Pediatric Uveitis Patients
    Tekin, Zahide Ekici
    Yener, Gulcin Otar
    Akbulut, Selen
    Cetin, Ebru Nevin
    Yuksel, Selcuk
    TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY, 2021, 51 (06): : 351 - 357
  • [44] Clinical outcome of chronic immunosuppression in patients with non-infectious uveitis
    Menezo, V
    Lau, C
    Comer, M
    Lightman, S
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2005, 33 (01): : 16 - 21
  • [45] Immunosuppressive chemotherapy for non-infectious uveitis
    Calonge, M
    Bringas, R
    Herreras, JM
    SOE '97 - XI CONGRESS OF THE EUROPEAN SOCIETY OF OPHTHALMOLOGY, VOLS 1 AND 2, 1997, : 643 - 648
  • [46] Adalimumab in the treatment of non-infectious uveitis
    Burek-Michalska, Alicja
    Turno-Krecicka, Anna
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 29 (10): : 1231 - 1236
  • [47] Rituximab for non-infectious Uveitis and Scleritis
    Ng, Caleb C.
    Sy, Aileen
    Cunningham, Emmett T., Jr.
    JOURNAL OF OPHTHALMIC INFLAMMATION AND INFECTION, 2021, 11 (01)
  • [48] Rituximab for non-infectious Uveitis and Scleritis
    Caleb C. Ng
    Aileen Sy
    Emmett T. Cunningham
    Journal of Ophthalmic Inflammation and Infection, 11
  • [49] Tocilizumab in adult non-infectious uveitis
    Lo, Tiffany
    Rogers, Sophie
    Ross, Laura
    Bosco, Julian
    Lim, Lyndell
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [50] Immunomodulatory Therapy for non-infectious Uveitis
    Heinz, C.
    OPHTHALMOLOGE, 2019, 116 (10): : 917 - 917